- Home
- PLXS vs VKTX Comparison
PLXS vs VKTX Comparison
Compare PLXS & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- VKTX
- Stock Information
- Founded
- PLXS 1979
- VKTX 2012
- Country
- PLXS United States
- VKTX United States
- Employees
- PLXS N/A
- VKTX N/A
- Industry
- PLXS Electrical Products
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLXS Technology
- VKTX Health Care
- Exchange
- PLXS Nasdaq
- VKTX Nasdaq
- Market Cap
- PLXS 3.8B
- VKTX 3.8B
- IPO Year
- PLXS 1986
- VKTX 2015
- Fundamental
- Price
- PLXS $143.89
- VKTX $36.90
- Analyst Decision
- PLXS Buy
- VKTX Strong Buy
- Analyst Count
- PLXS 4
- VKTX 14
- Target Price
- PLXS $157.50
- VKTX $87.00
- AVG Volume (30 Days)
- PLXS 181.4K
- VKTX 4.6M
- Earning Date
- PLXS 10-22-2025
- VKTX 10-22-2025
- Dividend Yield
- PLXS N/A
- VKTX N/A
- EPS Growth
- PLXS 56.11
- VKTX N/A
- EPS
- PLXS 6.26
- VKTX N/A
- Revenue
- PLXS $4,032,966,000.00
- VKTX N/A
- Revenue This Year
- PLXS $10.09
- VKTX N/A
- Revenue Next Year
- PLXS $5.36
- VKTX N/A
- P/E Ratio
- PLXS $23.02
- VKTX N/A
- Revenue Growth
- PLXS 1.82
- VKTX N/A
- 52 Week Low
- PLXS $103.43
- VKTX $18.92
- 52 Week High
- PLXS $172.89
- VKTX $70.41
- Technical
- Relative Strength Index (RSI)
- PLXS 50.61
- VKTX 60.54
- Support Level
- PLXS $137.67
- VKTX $34.17
- Resistance Level
- PLXS $146.36
- VKTX $39.57
- Average True Range (ATR)
- PLXS 5.00
- VKTX 2.33
- MACD
- PLXS -0.46
- VKTX 0.01
- Stochastic Oscillator
- PLXS 41.38
- VKTX 73.03
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.